Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Immunol. 2010 Apr;10(4):248-56. doi: 10.1038/nri2742.

T(H)17 cells in tumour immunity and immunotherapy.

Author information

  • 1Department of Surgery, University of Michigan School of Medicine, Ann Arbor, 48109-0669, USA. wzou@med.umich.edu

Erratum in

  • Nat Rev Immunol. 2011;11(8):565.

Abstract

T helper 17 (T(H)17) cells have well-described roles in autoimmune disease. Recent evidence suggests that this effector T cell subset is also involved in tumour immunology and may be a target for cancer therapy. In this Review, we summarize recent findings regarding the nature and relevance of T(H)17 cells in mouse models of cancer and human disease. We describe the interplay between T(H)17 cells and other immune cells in the tumour microenvironment, and we assess both the potential antitumorigenic and pro-tumorigenic activities of T(H)17 cells and their associated cytokines. Understanding the nature of T(H)17 cell responses in the tumour microenvironment will be important for the design of more efficacious cancer immunotherapies.

PMID:
20336152
[PubMed - indexed for MEDLINE]
PMCID:
PMC3242804
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Write to the Help Desk